E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
Status:
Recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study of E6201 plus dabrafenib for the treatment of CNS metastases in BRAF
V600-mutated metastatic melanoma. A total of up to N=28-34 subjects with melanoma
metastasized to the CNS will be included.